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A B S T R A C T   
Importance: Among COVID-19 cases, especially the (frail) elderly show a high number of severe infections, 
hospital admissions, complications, and death. The highest mortality is found between 80 and 89 years old. Why 
do these patients have a higher risk of severe COVID-19? In this narrative review we address potential mech-
anisms regarding viral transmission, physical reserve and the immune system, increasing the severity of this 
infection in elderly patients. 
Observations: First, the spread of COVID-19 may be enhanced in elderly patients. Viral shedding may be 
increased, and early identification may be complicated due to atypical disease presentation and limited testing 
capacity. Applying hygiene and quarantine measures, especially in patients with cognitive disorders including 
dementia, can be challenging. Additionally, elderly patients have a decreased cardiorespiratory reserve and are 
more likely to have co-morbidity including atherosclerosis, rendering them more susceptible to complications. 
The aging innate and adaptive immune system is weakened, while there is a pro-inflammatory tendency. The 
effects of SARS-CoV-2 on the immune system on cytokine production and T-cells, further seem to aggravate this 
pro-inflammatory tendency, especially in patients with cardiovascular comorbidity, increasing disease severity. 
Conclusions and relevance: The combination of all factors mentioned above contribute to the disease severity 
of COVID-19 in the older patient. While larger studies of COVID-19 in elderly patients are needed, understanding 
the factors increasing disease severity may improve care and preventative measures to protect the elderly patient 
at risk for (severe) COVID-19 in the future.   
1. Introduction 
On November 18th 2020, there have been over 55 million confirmed 
cases of SARS-CoV-2 infection causing COVID-19, with up to 1.3 million 
deaths worldwide. In the Netherlands alone, there are up to 8,600 
registered deaths, a number that is still on the rise. The risk of hospi-
talization and death increases with age,1-3 illustrated by a case fatality 
rate increase from a 2.3% in the general population, to 14.8% in patients 
over 80 years old.4 A contact survey study from Wuhan and Shanghai 
found the highest susceptibility to infection in individuals older than 65 
year.5 While patients over 65 years old comprise 17% of the total pop-
ulation in the United States of America, they make up 31% of COVID-19 
cases, 45% of the associated hospitalizations, 53% of intensive care unit 
admissions, and 80% of deaths.6 
The highest mortality rate in the Netherlands is found in the age 
group between 80 and 89 years and among frail patients receiving 
chronic medical care in nursing home facilities through the Dutch long- 
term-care-act.1,7 Since polymerase chain reaction (PCR)-testing was 
limited in the beginning of the pandemic, especially in this patient 
group, it is likely that the total number of COVID-19-attributable cases 
and deaths are underestimated. During the (first) outbreak of the 
pandemic, the mortality rate in this group of patients increased from 1, 
160 to 2,400 deaths a week with a mortality excess of 53%.1,7 In Europe, 
the all-cause excess mortality from week 1 to 18 in 2020 was an 
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astonishing 185,287, of which 48% occurred in patients 85 years or 
older.8 This may directly be caused by COVID-19, or indirectly from 
delay in diagnosis and treatment due to decreased accessibility of 
healthcare. Important reasons for decreased accessibility were down-
scaling inpatient and outpatient (elective) care to prevent further spread 
of the infection, strain on the medical capacity due to an increase in 
COVID-19-related care, and fear of patients to seek medical care during 
the pandemic. 
Compared with younger cases, patients over 65 years old show 
higher pulmonary severity index scores, multiple lobe involvement on 
CT-scan and a higher rate of acute respiratory distress syndrome 
(ARDS).9 A small study including relatively few deaths (17 patients) 
shows that the median time from occurrence of the first symptom to 
death might be shorter in patients aged over 70 years, compared with 
younger patients (median 12 versus 20 days).10 Thus, in elderly patients, 
COVID-19 is associated with more severe (pulmonary) complications 
and with a higher mortality rate. In this narrative review we address the 
issue: Why do elderly patients have a higher risk of severe COVID-19? 
2. Viral exposure 
2.1. Increased viral shedding 
One of the mechanisms explaining the large incidence in older 
COVID-19 patients, especially in nursing homes, might be increased 
viral shedding. In Influenza A and B infection, viral load is significantly 
higher in children <1 year and individuals > 65 years old, compared 
with other age groups.11 Viral shedding of SARS-CoV (which caused the 
SARS epidemic) also seems to increase with age.12 Increased viral 
shedding has been found for SARS-CoV-2 as well. A small study of 26 
cases from Hong Kong detected higher peak viral load in respiratory 
specimens of older COVID-19 patients.13 More severe COVID-19 may be 
associated with higher viral loads, and patients with more severe 
COVID-19 are older than patients with milder infections (mean age 56 
versus 44 years old).14 Since older patients have higher peak viral loads, 
they are likely to shed more virus. The cause of increased viral loads in 
the elderly is not fully clear but may be the result of the effects of aging 
on both airway clearance and the immune system as described below. 
2.2. Atypical presentation 
The majority of elderly patients at the emergency department has an 
atypical presentation of illness including falls and may lack any specific 
symptoms of the underlying COVID-19.15 Patients may not develop a 
fever in the case of infection and may only show cognitive or functional 
decline, especially patients with pre-existing cognitive disorders. In a 
case series of 19 patients with COVID-19 admitted to a geriatric unit 
with a mean age of 84 years, 79% of the patients presented with a 
delirium and 32% with a fall, while only a minority showed typical 
symptoms like coughing (26%) and fever (37%).16 Atypical pre-
sentations of SARS-CoV-2 are frequent and may delay diagnosis in 
elderly patients. In the first weeks of the pandemic, the diagnosis could 
have been further delayed because PCR-testing for SARS-CoV-2 avail-
ability was limited. This was especially the case for patients at home or 
in nursing homes, further complicating the early identification of 
infected individuals and thus facilitating viral transmission. 
2.3. Difficulty to ensure quarantine 
In nursing homes, outbreaks of viral gastrointestinal and respiratory 
infections occur frequently and may be related to close contact of pa-
tients with care providers during care and assistance, and other resi-
dents.17,18 There were multiple outbreaks of COVID-19 reported within 
nursing homes during the first wave of the pandemic. Both lack of 
PCR-test possibilities and a shortage in personal protective materials for 
care providers contributed to these outbreaks. Furthermore, protective 
measures to prevent infection, e.g., frequent handwashing and cough-
ing/sneezing in the elbow, are difficult to introduce to patients with 
cognitive impairments such as dementia. Quarantining infected in-
dividuals is often challenging, as cognitively impaired patients may have 
an urge to wander. Furthermore, patients may suffer from anxiety and 
agitation when applying isolation, especially when they do not have the 
cognitive capabilities to understand the need for this type of 
measurements. 
Taken together, older patients may have higher viral shedding. Older 
and frail patients may present with atypical symptoms and may make it 
difficult to quickly identify infected individuals. Preventing spread of 
the infection by adequate hygiene measures and applying quarantine 
when needed may be difficult in patients with cognitive capabilities, 
especially when there is a shortage in testing and personal protective 
materials. 
3. Co-morbidity 
With aging, the prevalence of various diseases increases, e.g., res-
piratory diseases including chronic obstructive pulmonary disease, 
diabetes mellitus and cardiovascular disease (CVD). Over half of patients 
over 75 years old in the Netherlands have multiple chronic diseases.19 
The increase in co-morbidity and the decrease in physiological reserve in 
the elderly may increase the risk of severe (viral) infections and 
complications. 
3.1. Respiratory co-morbidity 
Aging is associated with a decrease in lung volumes, decreased res-
piratory muscle function (including the diaphragm) and cough 
strength.20 Furthermore, protective mechanisms like mucociliary 
clearance may be diminished.21 Mucociliary clearance encompasses the 
action of ciliated cells in the upper and lower airway to clear mucus and 
particles out of the lungs. A study in 90 healthy adults showed decreased 
nasal mucociliary clearance time and increased ciliary disarrangement 
with increasing age.21 Also, the clearance of radiolabeled particles out of 
the small airways was negatively associated with age.22 These 
age-related changes including decreased pulmonary reserve and airway 
clearance may partially explain the increased frequency and severity of 
(any) pulmonary infection. 
3.2. Cardiovascular and cerebrovascular co-morbidity 
Pre-existing hypertension, diabetes, and cardiovascular disease are 
all associated with more severe COVID-19.23,24 The correlation between 
co-morbidity and disease severity is not yet fully understood, but poor 
outcome is associated with pre-existing atherosclerosis, down regulation 
of angiotensin-converting enzyme 2 (ACE2) and local 
renin-angiotensin-aldosteron system (RAAS) activation (see dysfunc-
tional immune response below). In a study of 138 hospitalized patients, 
elevated cardiac biomarkers and echocardiography abnormalities were 
present in 7.2% of all COVID-19 cases and in 22% in severe COVID-19 
cases.25 Respiratory infections in general are associated with an 
increased risk of cardiac infarction.26 Myocarditis and stress cardiomy-
opathy have been proposed as a cause of cardiac injury in COVID-19.27 
Infection induces inflammatory cytokines, such as interleukins 1, 6, and 
8, and TNF-alpha, which can activate inflammatory cells in atheroscle-
rotic plaques.26 Furthermore, COVID-19 is associated with a pro-
thrombogenic state and with an increase in arterial and venous 
thrombotic complications.28-30 In a case series of six patients with 
COVID-19 and acute ischemic stroke, five had a history of cardiovas-
cular disease including hypertension, ischemic heart disease, stroke, and 
atrial fibrillation.31 In a retrospective observational study in Wuhan in 
214 patients, patients with more severe COVID-19 were older and 
showed a higher rate of stroke (5.7 versus 0.8%).32 In the United 
Kingdom, among 125 patients with neurological complications with 
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COVID-19, 62% consisted of an cerebrovascular accident (74% 
ischemic, 12% hemorrhagic).33 Among these patients, 82% was over the 
age of 60. Thus, this type of viral pneumonia in an elderly patient, 
especially with atherosclerosis and a history of cardiovascular disease, 
seem to increase the risk of developing cardio- and cerebrovascular 
complications. 
3.3. Frailty 
Frailty is defined as a geriatric syndrome characterized by an 
increased risk/vulnerability for developing adverse clinical outcomes 
like dependency and/or death. Frailty can be caused by and influenced 
by factors like comorbidity, decreased functional reserve, nutritional 
status, muscle weakness, physical activity, and mental state. Higher 
frailty scores, including in sepsis, are associated with worse patient 
outcomes like mortality and morbidity.34-37 The COPE study included 
772 (49.4%) frail patients with COVID-19 with a median age of 74 
year.38 Higher clinical frailty scale (CFS) was associated with both 
higher mortality and longer time from hospital admission to discharge 
compared to patients with low CFS. The pulmonary, cardiac, and/or 
neurologic co-morbidity mentioned above may cause or worsen the 
frailty ‘status’ of an elderly patient. Interestingly, frailty is correlated 
with higher levels of IL-6, CRP and TNF-α.39,40 Frailty in the elderly 
appears to be in close association with chronic inflammation, where 
chronic inflammation may contribute to worsen physical reserve and 
limit resilience in the elderly patient. In several countries, nationwide 
intensive care protocols included high age and CFS as a relative 
contra-indication for intubation in COVID-19, due to scarcity of inten-
sive care beds during the first peak of the pandemic combined with the 
high mortality and high risk of further increasing frailty and dependence 
in activities of daily living in this patient group.41,42 
4. Dysfunctional immune response 
4.1. Reduced ACE2 
In viral infections, viral and host membranes fuse after binding with 
a receptor, viral genetic material enters the cell and the virus multiplies 
itself in the host cell. The spike protein receptor-binding domain of 
SARS-CoV-2 is a ligand of the receptor of ACE2.43 ACE2 is expressed in 
the lung, heart, kidney, blood vessels, brain, intestine and in fat tissue. 
SARS-CoV-2 may directly infect endothelial cells via ACE2. Since these 
endothelial cells and the glycocalyx regulate vessel wall integrity, 
coagulation and vascular tone, infection may induce inflammatory cell 
infiltration and microvascular prothrombotic effects.44 The D-dimer, an 
acute phase reactant and marker of activated coagulation, has been 
found to be frequently elevated in patients with COVID-19 and predic-
tive of adverse outcomes.3 A study regarding autopsy of 21 patients with 
COVID-19 showed that organs were mainly affected by an inflammatory 
response.45 In the majority of patients (83%), endotheliitis and micro-
thrombi were present in the lungs, next to neutrophilic infiltrates in the 
lungs and other organs.45 ACE2 is down-regulated on cell surfaces after 
binding with the SARS-CoV-2 spike protein.46,47 ACE2 has an 
anti-inflammatory effect by converting angiotensin II to 
angiotensin-(1–7). Angiotensin II has pro-inflammatory properties and 
may mediate acute lung injury through vasoconstriction and increased 
vascular permeability. Down-regulation of ACE2 may result in angio-
tensin II accumulation and local RAAS activation and vascular perme-
ability, which might contribute to the lung damage.47 Additionally, 
ACE2 expression may decrease with increasing age and in persons with 
CVD.48-50 The use of ACE inhibitors and angiotensin-receptor blockers, 
which may upregulate ACE2 expression, has not been shown to affect 
the risk of severe COVID19.51,52 Thus, reduced ACE2 may exaggerate 
pulmonary inflammation in the elderly, especially those with CVD. 
4.2. Immunaging 
After infection with a virus, infected cells produce type I interferons 
(e.g., IFN-α and IFN-β), by transcription of the interferon genes induced 
by phosphorylation of interferon regulatory transcription factor (IRF) 3 
and 7. These type I interferons lower the susceptibility of neighboring 
cells to viral infection and activate natural killer cells and Th1- 
lymphocytes, amplifying the anti-viral response. In human monocytes 
of older donors infected with influenza A, type 1 interferon production 
seems impaired with diminished IRF-3 and -7 phosphorylation, but pro- 
inflammatory TNF-α production was preserved.53 Interestingly, 10.2% 
of the patients with severe COVID-19 showed presence of neutralizing 
auto-antibodies against type I interferons and 3.5% had genetic muta-
tions in loci regarding type I interferon immunity.54,55 The presence of 
auto-antibodies was more prevalent in patients over 65 years old, 
implying an effect of age.54 
Severe cases of COVID-19 including patients requiring intensive care 
admission showed higher levels of TNF-α, among other pro- 
inflammatory cytokines like interleukin-6 (IL-6).56,57 This over-
expression, in early research in the pandemic referred to as a ‘cytoki-
ne-storm’, is a feature of severe COVID-19, and might contribute to the 
development of ARDS and multi-organ failure.58 In a study in 48 pa-
tients in Wuhan, detectable serum viral RNA was associated with higher 
levels of IL-6 and increased severity of COVID-19 in critically ill patients. 
The group of critically ill patients seemed older, though not statistically 
significant, than the patients with moderate to severe disease (80 years 
vs 53 and 64 years old).59 Aging is characterized by chronic, low-grade 
inflammation, also referred to as inflammaging.60,61 In a prospective 
population-based study of 1155 patients age 65-102 years, a stratified 
inflammatory index using IL-6 and TNF-α-receptor 1 levels could predict 
10-year mortality.62 It remains to be determined whether this cytokine 
storm is the cause of or a symptom of severe COVID-19, or maybe even of 
aging. Taken together, diminished type I interferons production and 
pre-existing low-grade inflammation with pro-inflammatory cytokines 
might tilt the immune status of the elderly patient to a more 
pro-inflammatory status. 
4.3. Immunosenescence 
With aging, migration, chemotaxis and phagocytosis of the innate 
immune system including neutrophils, macrophages, and dendritic cells, 
decreases.60,61,63 While the number of circulating T-cells of the adaptive 
cellular immune system remains relatively constant with age, there is a 
shift in T-cell subpopulations leading to a decrease in naïve T-cells and 
increase in memory T-cells, which limits the response against novel in-
fectious agents.63,64 Expression of CD28, a costimulatory receptor in 
T-cells, decreases with age, what is associated with a weakened immune 
responses.63,64 Higher TNF-α with aging inhibits CD28 expression, 
contributing to further T-cell dysregulation.65 Further suppression of the 
adaptive immunity, is caused by lymphopenia, a hallmark phenomenon 
seen in COVID-19, reducing the number of total, CD4+, and CD8+ T 
cells.66 In conclusion, both the innate and the adaptive cellular immune 
system of the older patient is weakened (immunosenescence), with a 
pro-inflammatory tendency (inflammaging), which seems to be intensi-
fied during COVID-19, increasing disease severity.61,66-68 
5. Conclusion 
In this narrative review, we discuss several features of COVID-19 and 
aging to clarify the increased mortality in older patients, summarized in 
Figure 1. This review does not cover all of the aspects of COVID-19 and 
those of the aging immune system. There are still aspects unknown, and 
while it is theoretically plausible that changes seen in the aging immune 
system are causatively related to disease severity, further studies are 
required. Also, many of the studies on comorbidity and complications 
encompass relatively small numbers of elderly patients and need to be 
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confirmed in prospective observational studies. Especially the frail 
elderly show a higher number of severe infections, requiring hospital 
admission, and leading to death. Elderly patients may show high viral 
shedding. Furthermore, ways to limit spread of the infection by early 
identification may be complicated due to atypical disease presentation 
and has been limited by lack of testing capacity in the recent past. Op-
portunities to apply quarantine measures in patients with cognitive 
disorders can be limited. Elderly patients have a decreased cardiore-
spiratory reserve and are more likely to have co-morbidity including 
atherosclerosis, rendering them more susceptible to complications. The 
aging innate and adaptive immune system is weakened, while there is a 
pro-inflammatory tendency. The combination of these factors contrib-
utes to the disease severity of COVID-19 in the older patient. Under-
standing these aspects may help to improve preventive measures and 
care of the older patient at risk for (severe) COVID-19 in the future. 
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